CClinicalTrials.gg
Status unknownNCT05503940Updated Sep 2, 2022

Association of Multiple Medications With the Severity of Dyspepsia

An observational study in Dyspepsia, sponsored by Air Force Military Medical University, China. Status unknown at 4 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-09-02.

Sponsored by Air Force Military Medical University, China · Observational

The sponsor has not verified this record recently (last verified Aug 2022), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
600
Ages
18 Years and older
Sex
All
01

Study summary

Dyspepsia is a very common gastrointestinal disease. Some medications, were associated with higher frequent incidences of dyspepsia, including non-steroid anti-inflammatory drugs (NSAIDs), Bisphosphonates, Tetracyclines, et al. Multiple medications were suggested to be strongly relate to adverse drug events (ADEs), adverse drug reactions (ADRs), drug-drug interactions, and drug-disease interactions, which may cause gastrointestinal(GI) dysfunction or injury to the GI mucosa. However, it was unclear whether multiple medications was associated with more severe symptoms of dyspepsia and dyspepsia-based score systems.

02

Conditions studied

  • Dyspepsia

Browse trials for

03

In context

Dyspepsia

363 studies on the registry are indexed under Dyspepsia; 51 are open to participants now.

This study's planned enrollment of 600 is above the median of 192 across 56 observational studies indexed under Dyspepsia.

Browse Dyspepsia studies →

Lead sponsor

Air Force Military Medical University, China is the lead sponsor of 172 studies on the registry; 36 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients aged ≥ 18 years old who met broad criteria of dyspepsia were eligible for our study.

Inclusion criteria

  1. aged ≥18 years old
  2. Patients who met broad criteria of dyspepsia

Exclusion criteria

Exclusion Criteria:

  1. organ failure defined by Marshall standard
  2. severe psychiatric illnesses
  3. suspected or identified bowel obstruction
  4. known malignancy
  5. pregnancy or lactation
  6. unable to provide consent
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
600 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. The rate of patients with severe dyspepsia judged by patients

    Patients rated the severity of dyspepsia as mild, moderate, and severe by themselves

    Time frame: 1 day

Secondary outcomes

  1. Global Overall Symptom score (GOSS)

    The GOSS consists of 10 cardinal items (epigastric pain, epigastric discomfort, Heartburn, acid regurgitation, upper abdominal bloating, belching, nausea, early satiety, postprandial fullness, other epigastric symptoms(eg. epigastric burning). Each item can be scored from 1 (no) to 7 (worst).

    Time frame: 1 days

  2. Functional dyspepsia

    Functional dyspepsia was defined by Rome IV criteria. Patients diagnosed as Rome IV criteria met the following criteria: by one or more of the following symptoms: postprandial fullness, early satiation, epigastric pain, and epigastric burning that are unexplained after a routine clinical evaluation, Criteria fulfilled for the last 3 months with symptom onset at least 6 months before diagnosis.

    Time frame: 1 days

  3. organic upper gastrointestinal (GI) diseases.

    All included patients underwent upper GI endoscopy and abdominal ultrasound and H. Pylori test. Barrett's esophagus, esophageal candidiasis, esophageal cancer, gastric ulcer, gastric erosion, gastric cancer, duodenal ulcer, duodenal erosion, cholecystitis, pancreatitis and biliary stones were classified as organic upper GI diseases.

    Time frame: 1 day

  4. subtypes of functional dyspepsia

    functional dyspepsia was classified into three subgroups:(1) Postprandial Distress Syndrome, defined as Bothersome postprandial fullness or/and Bothersome early satiation. (2) Bothersome epigastric pain AND/OR Bothersome epigastric burning. (3) mixed syndrome, defined when postprandial distress syndrome and epigastric pain syndrome presented simultaneously.

    Time frame: 6 months

  5. Short Form of Nepean Dyspepsia Index (SF-NDI)

    The SF-NDI consists of 10 questions regarding the effects of dyspepsia symptoms ("stomach problems") on different aspects of life (tension, interference with daily activities, eating/drinking, knowledge/control, and work/study). Each response can be from 1 (not at all affected) to 5 (extremely affected), or 0 (N/A), for a total summed score out of 50.

    Time frame: 1 day

  6. Hospital anxiety and depression scale

    Anxiety and depression of patients are assessed by using Hospital Anxiety and Depression Scale.It contains 14 items (7 anxiety and 7 depression), which assess symptoms experienced during the past week on a 0-3 scale. A subscore of \> 8 for depression or anxiety would indicate a clinical case.

    Time frame: 1 day

  7. Quality of Life scores

    Quality of Life scores assessed by Patient-reported outcomes measurement information system (PROMIS) Global-10 questionnaire.PROMIS Global-10 is a newly validated 10-question survey used to assess health care-related quality of life measures for the general population. It's a 10-item patient-reported questionnaire in which the response options are presented as 5-point (as well as a single 11-point) rating scales. These scores are then standardized to the general population, using the "T-Score". The average "T-Score" for the United States population is 50 points, with a standard deviation of 10 points. Higher scores indicate a healthier patient and a better quality of life.

    Time frame: 1 day

  8. Number of Participants with other functional gastrointestinal diseases

    Other functional gastrointestinal diseases,such as irritable bowel syndrome(IBS) or functional heartburn,etc.

    Time frame: 1 day

  9. Functional dyspepsia symptom diary (FDSD) score

    The FDSD consists of 5 cardinal items (burning in the stomach, stomach pain, bloating, postprandial fullness, and early satiety) and 3 supplementary items (nausea, burping/belching rating, and burping/belching bother). Each item can be scored from 0 (no) to 10 (worst). Total Symptom Score includes the 5 cardinal items and ranges from 0 to 50

    Time frame: 1 days

07

Study locations

1 of 4 sites recruiting
  • Lanzhou University Second Hospital
    Lanzhou, Gansu, China
    • Xiaojun Huang, M.D. · Contact
    Not yet recruiting
  • The Second Affiliated Hospital of Xi'an Jiaotong University
    Xi'an, Shaanxi 710032, China
    • Na Liu, M.D. · Contact
    Not yet recruiting
  • Xijing 986 Hospital
    Xi'an, Shaanxi 710032, China
    • Jun Wang, M.D. · Contact
    Not yet recruiting
  • Xijing Hospital of Digestive Diseases
    Xi'an, Shaanxi 710032, China
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 2, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05503940
Lead sponsor
Air Force Military Medical University, China
Responsible party
Yanglin Pan (professor, Air Force Military Medical University, China) — Principal investigator
First posted
Aug 17, 2022
Start date
Jun 1, 2022
Primary completion
Dec 31, 2023 (estimated)
Completion
Jun 1, 2024 (estimated)
Last update
Sep 2, 2022

Study contacts

Yanglin Pan
Contact
yanglinpan@hotmail.com
13991811225

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion